These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30735565)

  • 21. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
    Komizo T; Ono T; Yagi A; Miyata K; Aihara M
    Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.
    Kirihara T; Taniguchi T; Yamamura K; Iwamura R; Yoneda K; Odani-Kawabata N; Shimazaki A; Matsugi T; Shams N; Zhang JZ
    Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):145-153. PubMed ID: 29332128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys.
    Tokushige H; Inatani M; Nemoto S; Sakaki H; Katayama K; Uehata M; Tanihara H
    Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):3216-22. PubMed ID: 17591891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction Between Pilocarpine and Ripasudil on Intraocular Pressure, Pupil Diameter, and the Aqueous-Outflow Pathway.
    Yamagishi-Kimura R; Honjo M; Komizo T; Ono T; Yagi A; Lee J; Miyata K; Fujimoto T; Inoue T; Tanihara H; Nishida J; Uchida T; Araki Y; Aihara M
    Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1844-1854. PubMed ID: 29677344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension.
    Feldman RM
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):23-35. PubMed ID: 12648301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of 8-iso prostaglandin E2 on aqueous humor dynamics in monkeys.
    Wang RF; Lee PY; Mittag TW; Podos SM; Serle JB; Becker B
    Arch Ophthalmol; 1998 Sep; 116(9):1213-6. PubMed ID: 9747682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
    Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ripasudil: first global approval.
    Garnock-Jones KP
    Drugs; 2014 Dec; 74(18):2211-5. PubMed ID: 25414122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
    Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
    J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
    [No Abstract]   [Full Text] [Related]  

  • 30. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
    Inoue T; Tanihara H
    Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.
    Tanna AP; Johnson M
    Ophthalmology; 2018 Nov; 125(11):1741-1756. PubMed ID: 30007591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys.
    Sumi K; Inoue Y; Nishio M; Naito Y; Hosoya T; Suzuki M; Hidaka H
    Bioorg Med Chem Lett; 2014 Feb; 24(3):831-4. PubMed ID: 24412071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
    Serle JB; Katz LJ; McLaurin E; Heah T; Ramirez-Davis N; Usner DW; Novack GD; Kopczynski CC;
    Am J Ophthalmol; 2018 Feb; 186():116-127. PubMed ID: 29199013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraocular pressure-lowering effects of imidazo[1,2-a]- and pyrimido[1,2-a]benzimidazole compounds in rats with dexamethasone-induced ocular hypertension.
    Marcus AJ; Iezhitsa I; Agarwal R; Vassiliev P; Spasov A; Zhukovskaya O; Anisimova V; Ismail NM
    Eur J Pharmacol; 2019 May; 850():75-87. PubMed ID: 30716317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of the Antiglaucoma Agent JV-GL1 and Related Compounds in the Canine Eye.
    Woodward DF; Coleman RA; Woodrooffe AJ; Spada CS; Wang JW
    J Ocul Pharmacol Ther; 2020 Oct; 36(8):636-648. PubMed ID: 32640926
    [No Abstract]   [Full Text] [Related]  

  • 36. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action.
    Sharif NA
    Curr Drug Targets; 2010 Aug; 11(8):978-93. PubMed ID: 20426763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
    Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rho kinase inhibitors for glaucoma treatment - Review.
    Germano RA; Finzi S; Challa P; Susanna Junior R
    Arq Bras Oftalmol; 2015; 78(6):388-91. PubMed ID: 26677046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
    Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
    Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.
    Adelli GR; Bhagav P; Taskar P; Hingorani T; Pettaway S; Gul W; ElSohly MA; Repka MA; Majumdar S
    Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2167-2179. PubMed ID: 28399267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.